{"disease":{"id":"hereditary-factor-viii-deficiency-disease","name":"Hereditary factor VIII deficiency disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":14,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"emicizumab","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hemlibra","generic_name":"EMICIZUMAB","company_name":"Roche","drug_phase":"marketed","molecular_target":"Coagulation factor IX","drug_class":"","quality_score":63,"revenue":"4800","mechanism":"Hemlibra works by binding to and activating factor IXa, a protein involved in blood clotting, to bypass the need for factor VIII."},{"drug_id":"eptacog-alfa-activated","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eptacog Alfa","generic_name":"EPTACOG ALFA (ACTIVATED)","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"minirin","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minirin","company_name":"Hormozgan University of Medical Sciences","drug_phase":"marketed","molecular_target":"Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"efmoroctocog-alfa","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elocta","generic_name":"EFMOROCTOCOG ALFA","company_name":"Swedish Orphan Biovitrum AB","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"valoctocogene-roxaparvovec","indication_name":"Severe hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roctavian","generic_name":"VALOCTOCOGENE ROXAPARVOVEC","company_name":"BioMarin International Limited","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":43,"revenue":null,"mechanism":"Roctavian introduces a functional copy of the F8 gene into cells to produce factor VIII protein."},{"drug_id":"moroctocog-alfa","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Refacto Af","generic_name":"MOROCTOCOG ALFA","company_name":"Pfizer Ltd","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"turoctocog-alfa","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novoeight","generic_name":"TUROCTOCOG ALFA","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"octocog-alfa","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advate","generic_name":"OCTOCOG ALFA","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"simoctocog-alfa","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuwiq","generic_name":"SIMOCTOCOG ALFA","company_name":"Octapharma AB","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"desmopressin","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ddavp","generic_name":"DESMOPRESSIN","company_name":"Ferring Pharms Inc","drug_phase":"marketed","molecular_target":"Vasopressin V1b receptor","drug_class":"Factor VIII Activator","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"eloctate","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eloctate","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"argipressin","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Argipressin","company_name":"Kristina Svennerholm","drug_phase":"marketed","molecular_target":"Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"esperoct","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Esperoct","company_name":"Novo Nordisk A/S","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lonoctocog-alfa","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afstyla","generic_name":"LONOCTOCOG ALFA","company_name":"CSL Behring GmbH","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"nuwiq","indication_name":"Hereditary factor VIII deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nuwiq","company_name":"Emory University","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":15,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04165135","title":"An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04158648","title":"A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}